001     173317
005     20210129214619.0
024 7 _ |a 10.1074/jbc.M114.560920
|2 doi
024 7 _ |a 0021-9258
|2 ISSN
024 7 _ |a 1083-351X
|2 ISSN
024 7 _ |a WOS:000341017200057
|2 WOS
037 _ _ |a FZJ-2014-06727
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Gruning, C. S. R.
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Alternative Conformations of the Tau Repeat Domain in Complex with an Engineered Binding Protein
260 _ _ |a Bethesda, Md.
|c 2014
|b Soc.
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1418303335_4288
|2 PUB:(DE-HGF)
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|0 0
|2 EndNote
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a article
|2 DRIVER
520 _ _ |a The aggregation of tau into paired helical filaments is involved in the pathogenesis of several neurodegenerative diseases including Alzheimer disease. The aggregation reaction is characterized by conformational conversion of the repeat domain, which partially adopts a cross-β structure in the resulting amyloid-like fibrils. Here we report the selection and characterization of an engineered binding protein, β-wrapin TP4, targeting the tau repeat domain. TP4 was obtained by phage display using the four-repeat tau construct K18ΔK280 as a target. TP4 binds K18ΔK280 as well as the longest isoform of human tau, htau40, with nanomolar affinity. NMR spectroscopy identified two alternative TP4-binding sites in the four-repeat domain, each including two hexapeptide motifs with high β-sheet propensity. Both binding sites contain the aggregation-determining PHF6 hexapeptide within repeat 3. In addition, one binding site includes the PHF6* hexapeptide within repeat 2, whereas the other includes the corresponding hexapeptide tau(337-342) within repeat 4, denoted PHF6**. Comparison of TP4-binding with tau aggregation reveals that the same regions of tau are involved in both processes. TP4 inhibits tau aggregation at substoichiometric concentration, demonstrating that it interferes with aggregation nucleation. This study provides residue-level insight into the interaction of tau with an aggregation inhibitor and highlights the structural flexibility of tau.
536 _ _ |a 452 - Structural Biology (POF2-452)
|0 G:(DE-HGF)POF2-452
|c POF2-452
|f POF II
|x 0
588 _ _ |a Dataset connected to CrossRef, juser.fz-juelich.de
700 1 _ |a Mirecka, E. A.
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Klein, A. N.
|0 P:(DE-Juel1)145785
|b 2
700 1 _ |a Mandelkow, E.
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Willbold, D.
|0 P:(DE-Juel1)132029
|b 4
700 1 _ |a Marino, S. F.
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Stoldt, M.
|0 P:(DE-Juel1)132023
|b 6
700 1 _ |a Hoyer, W.
|0 P:(DE-HGF)0
|b 7
|e Corresponding Author
773 _ _ |a 10.1074/jbc.M114.560920
|g Vol. 289, no. 33, p. 23209 - 23218
|0 PERI:(DE-600)1474604-9
|n 33
|p 23209 - 23218
|t The @journal of biological chemistry
|v 289
|y 2014
|x 1083-351X
856 4 _ |u http://www.jbc.org/content/early/2014/06/25/jbc.M114.560920
856 4 _ |u https://juser.fz-juelich.de/record/173317/files/FZJ-2014-06727.pdf
|y Restricted
909 C O |o oai:juser.fz-juelich.de:173317
|p VDB
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 2
|6 P:(DE-Juel1)145785
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 4
|6 P:(DE-Juel1)132029
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 6
|6 P:(DE-Juel1)132023
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 7
|6 P:(DE-HGF)0
913 2 _ |a DE-HGF
|b Key Technologies
|l BioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences
|1 G:(DE-HGF)POF3-550
|0 G:(DE-HGF)POF3-553
|2 G:(DE-HGF)POF3-500
|v Physical Basis of Diseases
|x 0
913 1 _ |a DE-HGF
|b Schlüsseltechnologien
|1 G:(DE-HGF)POF2-450
|0 G:(DE-HGF)POF2-452
|2 G:(DE-HGF)POF2-400
|v Structural Biology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF2
|l BioSoft
914 1 _ |y 2014
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)ICS-6-20110106
|k ICS-6
|l Strukturbiochemie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)ICS-6-20110106
980 _ _ |a UNRESTRICTED
981 _ _ |a I:(DE-Juel1)IBI-7-20200312


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21